Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review
Standard
Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review. / Reese, Kim-Lea; Pantel, Klaus; Smit, Daniel J.
In: J EXP CLIN CANC RES, Vol. 43, No. 1, 250, 02.09.2024.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review
AU - Reese, Kim-Lea
AU - Pantel, Klaus
AU - Smit, Daniel J
N1 - © 2024. The Author(s).
PY - 2024/9/2
Y1 - 2024/9/2
N2 - Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of early-stage PDAC that can be used for targeted screening approaches is available. Liquid biopsy allows the minimally invasive collection of body fluids (typically peripheral blood) and the subsequent analysis of circulating tumor cells or tumor-associated molecules such as nucleic acids, proteins, or metabolites that may be useful for the early diagnosis of PDAC. Single biomarkers may lack sensitivity and/or specificity to reliably detect PDAC, while combinations of these circulating biomarkers in multimarker panels may improve the sensitivity and specificity of blood test-based diagnosis. In this narrative review, we present an overview of different liquid biopsy biomarkers for the early diagnosis of PDAC and discuss the validity of multimarker panels.
AB - Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of early-stage PDAC that can be used for targeted screening approaches is available. Liquid biopsy allows the minimally invasive collection of body fluids (typically peripheral blood) and the subsequent analysis of circulating tumor cells or tumor-associated molecules such as nucleic acids, proteins, or metabolites that may be useful for the early diagnosis of PDAC. Single biomarkers may lack sensitivity and/or specificity to reliably detect PDAC, while combinations of these circulating biomarkers in multimarker panels may improve the sensitivity and specificity of blood test-based diagnosis. In this narrative review, we present an overview of different liquid biopsy biomarkers for the early diagnosis of PDAC and discuss the validity of multimarker panels.
KW - Humans
KW - Liquid Biopsy/methods
KW - Pancreatic Neoplasms/diagnosis
KW - Early Detection of Cancer/methods
KW - Biomarkers, Tumor/blood
KW - Carcinoma, Pancreatic Ductal/diagnosis
U2 - 10.1186/s13046-024-03166-w
DO - 10.1186/s13046-024-03166-w
M3 - SCORING: Review article
C2 - 39218911
VL - 43
JO - J EXP CLIN CANC RES
JF - J EXP CLIN CANC RES
SN - 1756-9966
IS - 1
M1 - 250
ER -